Decapeptide Combi-Therapy of (resistant) steroidal cancers
Steroid-related cancers have the highest incidence among tumors and its market potential for Europe and U.S.A. is estimated to be at least US$ 2.4 bn p.a. Scientists at the University of Göttingen developed novel proprietary decapeptidic antagonists to target GnRH-II receptor (which is highly expressed in steroidal cancers like e.g. breast, ovarian, endometrium and prostate carcinomas), which could be used in a combination cancer therapy and which potentially could also be used to treat malignant melanoma.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
